Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-01

Study Completion Date

2024-05-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is a randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and immunogenicity of three doses of GBS NN/NN2 with Alhydrogel® (Recombinant protein vaccine against Group B Streptococcus) in elderly participants aged 55 to 75.Participants will be followed up to 6 months after last vaccination.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Group B Streptococcus Vaccine in Healthy Females

NCT03807245

Group B Strep Infection

COMPLETED PHASE1

Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women

NCT01150123

Group B Streptococcus

COMPLETED PHASE1

Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine

NCT05005247

Group B Streptococcus Infection

COMPLETED PHASE1

Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.

NCT02459262

Infection by Streptococcus Group B

COMPLETED PHASE1

A Follow up Study of Group B Streptococcus (GBS)-NN/NN2 Vaccine in Healthy Volunteers

NCT06280157

Group B Streptococcus Infection

ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sixty (60) healthy older adult participants aged 55 to 75 years will be randomised in two cohorts; 30 obese and/or diabetic participants aged 55 to 75 years will be randomised in two cohorts.

Participants will be involved in the study for approximately one year including screening and safety follow-up.

Eligible participants will be administered a dose of GBS-NN/NN2 or placebo on three occasions: the first dose will be administered on Day 1, followed by the second and third doses 4 and 24 weeks later, respectively.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Group B Streptococcal Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1 - Active

Cohort 1 (30 healthy older adult) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).

Group Type EXPERIMENTAL

GBS-NN/NN2

Intervention Type BIOLOGICAL

GBS-NN/NN2 bound to alhydrogel as an adjuvant

Cohort 1 - Placebo

Cohort 1 (30 healthy older adult) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Normal Saline 0.9 %

Cohort 2 - Active

Cohort 2 (30 healthy older adult) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).

Group Type EXPERIMENTAL

GBS-NN/NN2

Intervention Type BIOLOGICAL

GBS-NN/NN2 bound to alhydrogel as an adjuvant

Cohort 2 - Placebo

Cohort 2 (30 healthy older adult) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Normal Saline 0.9 %

Cohort 3 - Active

Cohort 3 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).

Group Type EXPERIMENTAL

GBS-NN/NN2

Intervention Type BIOLOGICAL

GBS-NN/NN2 bound to alhydrogel as an adjuvant

Cohort 3 - Placebo

Cohort 3 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Normal Saline 0.9 %

Cohort 4 - Active

Cohort 4 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).

Group Type EXPERIMENTAL

GBS-NN/NN2

Intervention Type BIOLOGICAL

GBS-NN/NN2 bound to alhydrogel as an adjuvant

Cohort 4 - Placebo

Cohort 4 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Normal Saline 0.9 %

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GBS-NN/NN2

GBS-NN/NN2 bound to alhydrogel as an adjuvant

Intervention Type BIOLOGICAL

Placebo

Normal Saline 0.9 %

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants aged 55 to 75 years.
2. Body mass index (BMI) ≥18 and ≤30 kg/m2 for healthy participants, ≥ 30 to ≤45 kg/m2 for obese participants and ≥18 to ≤45 kg/m2 for type 2 diabetic participants.
3. Able to voluntarily provide written informed consent to participate in the study.
4. Female participants must be post-menopausal.
5. Participants capable and willing to follow trial schedule and procedures.

Exclusion Criteria

1. Participants who have received a GBS vaccine previously.
2. Participants with history or presence of significant (as evaluated by the investigator) cardiovascular disease, pulmonary, hepatic, gallbladder or biliary tract, renal, haematological, gastrointestinal, endocrine, immunologic, dermatological, neurological, psychiatric, autoimmune disease or current infection.

NOTE: Patients with type 2 diabetes are to be recruited for Cohort 3 and Cohort 4.
3. Laboratory values at screening which are deemed by the investigator to be clinically significantly abnormal.
4. Current or history of drug or alcohol abuse per investigator judgement.
5. Positive for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
6. Participants currently participating in a clinical trial.
7. Participants receiving an investigational drug, vaccine or device during the 90 days preceding the initial dose in this study.
8. Any significant illness during the 4 weeks preceding the vaccination visit, per investigator judgement.
9. Participants with a history of severe allergic reactions after previous vaccination.
10. Participants who have received any vaccine within 30 days of first IMP administration, or who are planning to receive any vaccine (eg, travel vaccines) up to 30 days after each vaccination.

NOTE: Exceptions could be made for emergency vaccinations (eg, tetanus) or vaccination campaigns (eg, SARS, CoV-2 or influenza) which will be permitted not less than 7 days before or after study vaccination.
11. Participants receiving immunosuppressive therapy or immunoglobulins in the 6 months prior to screening.
12. Participants within a 7-day period after an acute infection in the 7 days preceding vaccination, as per investigator judgement, or with fever (oral temperature \>37.9°C) in the 72 hours preceding vaccination.
13. Participants who have received antipyretics/analgesics treatment within 72 hours prior to dosing.
14. Participants on chronic medications that are likely to affect the assessments specified in the protocol (eg, anticoagulant therapy, systemic steroids).

NOTE: Chronic medications such as antihypertensives, bronchodilators, statins that do not affect the immune system, will be permitted and allowed to continue during the study at the discretion of the investigator. Treatment for diabetes will be continued as required for the diabetic participants recruited. Non-steroidal anti-inflammatory drugs or paracetamol will be permitted for the treatment of headache or other symptoms during the study. Use of over the counter (OTC) vitamins and dietary supplements is allowed.
15. Participants with skin defects and/or tattoos at the proposed site of vaccine administration.
16. Donation of blood or blood products within 90 days prior to first study vaccination.
17. Participants who, in the opinion of the Investigator, are unsuitable for participation in the study.
18. Involvement in the planning and/or conduct of the study (applies to both Sponsor personnel and/or personnel at the study centre or Clinical Research Organisation \[CRO\]).

Minimum Eligible Age

55 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes